Skip to main content
117 search results for:

Early-stage lung cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 06-06-2023 | Non-small-cell lung cancer | Conference coverage | Article
    ASCO 2023

    ADAURA demonstrates OS gain with adjuvant osimertinib in early-stage NSCLC

    Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR -mutated, early-stage non-small-cell lung cancer, show trial results.

  2. 18-08-2023 | Non-small-cell lung cancer | News | Article

    Combining SABR with immunotherapy prolongs early-stage NSCLC event-free survival

    Patients with treatment-naïve, early-stage or isolated parenchymal recurrent NSCLC benefit from the addition of immunotherapy to stereotactic ablative radiotherapy, indicate phase 2 results.

  3. 15-06-2023 | Non-small-cell lung cancer | News | Article
    ASCO 2023

    Interim KEYNOTE-671 findings support perioperative pembrolizumab for resectable NSCLC

    The KEYNOTE-671 trial points to a significant improvement in event-free survival for patients with early-stage, non-small-cell lung cancer with use of pembrolizumab before and after surgery.

  4. 28-07-2023 | Non-small-cell lung cancer | News | Article

    Atezolizumab may be beneficial for platinum-ineligible advanced NSCLC

    First-line treatment with atezolizumab significantly improves the overall survival of platinum-ineligible patients with locally advanced or metastatic non-small-cell lung cancer relative to chemotherapy.

  5. 05-09-2022 | Lung cancer | News | Article

    First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression

    Adding cemiplimab to first-line platinum-doublet chemotherapy significantly improves outcomes for patients with advanced non-small-cell lung cancer, regardless of tumor PD-L1 expression or histology, EMPOWER-Lung 3 study data show.

  6. 28-09-2022 | Lung cancer | News | Article

    Incidental sinoatrial node irradiation may increase AF risk in lung cancer

    Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.

  7. 11-05-2022 | Small-cell lung cancer | News | Article

    Durvalumab–CRT potential for limited-stage SCLC demonstrated

    Individuals with limited-stage small-cell lung cancer could benefit from the addition of durvalumab to chemoradiotherapy, suggest early data.

  8. 23-03-2022 | Non-small-cell lung cancer | News | Article

    Post-treatment ctDNA predicts poor outcomes in early-stage NSCLC

    The presence of circulating tumor DNA following treatment with curative intent for early-stage non-small-cell lung cancer is associated with an increased risk for relapse or death, LUCID study data show.

  9. 22-03-2022 | Non-small-cell lung cancer | News | Article

    ‘More effort needed’ to optimize use of standard early NSCLC therapies

    A US cohort study has identified low rates of use of certain standard treatments in patients with resectable, early-stage non-small-cell lung cancer.

  10. 23-08-2022 | Non-small-cell lung cancer | News | Article

    Real-world data confirm consolidation immunotherapy benefit for stage III NSCLC

    A US National Cancer Database analysis suggests that immunotherapy after chemoradiotherapy for unresectable stage III non-small-cell lung cancer is associated with an overall survival benefit in the general US population.

  11. 11-07-2022 | COVID-19 | News | Article

    Cancer screening declined globally during COVID-19 pandemic

    A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.

  12. 11-08-2022 | WCLC 2022 | Conference coverage | Article

    Sugemalimab continues to show stage III unresectable NSCLC benefits after chemoradiation

    Final analysis of progression-free survival in the GEMSTONE-301 trial shows a significant improvement with use of sugemalimab versus placebo after chemoradiotherapy for stage III unresectable non-small-cell lung cancer, report Chinese researchers at the IASLC World Conference on Lung Cancer 2022 in Vienna, Austria.

  13. 11-08-2022 | WCLC 2022 | Conference coverage | Article

    KEYNOTE-604 update bolsters first-line pembrolizumab–chemo for extensive-stage SCLC

    Adding pembrolizumab to etoposide plus platinum continues to improve the outcomes of treatment-naïve people with extensive-stage small-cell lung cancer in the long term, suggest follow-up data from KEYNOTE-604.

  14. 13-06-2022 | ASCO 2022 | Conference coverage | Article

    ctDNA identifies patients before late HR-positive breast cancer recurrence

    Circulating tumor DNA monitoring for minimal residual disease can identify patients at risk for distant relapse more than 5 years after diagnosis of high-risk, stage II–III hormone receptor-positive breast cancer, research shows.

  15. 19-04-2022 | AACR 2022 | Conference coverage | Article

    CheckMate 816 shows EFS boost with neoadjuvant nivolumab in resectable NSCLC

    Neoadjuvant treatment with nivolumab plus chemotherapy achieves significantly better event-free survival than chemotherapy alone, suggests the CheckMate 816 trial of patients with resectable non-small-cell lung cancer.

  16. play
    13-04-2022 | Non-small-cell lung cancer | Video

    PD-L1 expression in early NSCLC: Interpreting the data so far

    Heather Wakelee and Nasser Altorki discuss the current position on PD-L1 expression and immune checkpoint inhibition in early-stage, resectable NSCLC. 

  17. 07-04-2022 | Lung cancer | News | Article

    Research calls for radiation oncologist involvement in lung nodule management

    “These data do not suggest a rogue takeover of a thoracic multidisciplinary clinic by radiation oncologists during the last decade but, instead, illustrate the modern reality of the clinical management of early-stage [non-small-cell lung cancer], wherein up to one-third of patients cannot undergo surgery because of lower pulmonary function, low cardiovascular fitness, and/or advanced age or because they refuse surgery,” says Arvold.

  18. 16-03-2022 | Osimertinib | Adis Journal Club | Article
    Oncology and Therapy

    ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

    Since then, a number of trials have evaluated the role of TKI therapy in early-stage disease, with encouraging disease-free survival (DFS) results but lack of a survival advantage.

  19. 08-03-2022 | FDA | News | Article
    approvalsWatch

    Neoadjuvant nivolumab–chemo approved in USA for NSCLC

    medwireNews: Patients with resectable, early-stage non-small-cell lung cancer (NSCLC) may be given nivolumab with platinum-doublet chemotherapy prior to surgery, the US FDA has announced .

  20. 27-07-2021 | Non-small-cell lung cancer | News | Article

    Quitting smoking after lung cancer diagnosis improves survival outcomes

    Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.